DTILPRECISION BIOSCIENCES INC

Nasdaq precisionbiosciences.com


$ 10.48 $ -0.04 (-0.38 %)    

Friday, 13-Sep-2024 14:16:44 EDT
QQQ $ 474.74 $ 1.31 (0.28 %)
DIA $ 414.45 $ 1.82 (0.44 %)
SPY $ 561.34 $ 1.07 (0.19 %)
TLT $ 100.54 $ 0.06 (0.06 %)
GLD $ 238.74 $ 1.15 (0.49 %)
$ 10.49
$ 10.52
$ 10.45 x 100
-- x --
$ 10.36 - $ 10.52
$ 8.25 - $ 19.43
31,027
na
75.88M
$ 1.71
$ 4.47
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-01-2024 06-30-2024 10-Q
2 05-13-2024 03-31-2024 10-Q
3 03-27-2024 12-31-2023 10-K
4 11-07-2023 09-30-2023 10-Q
5 08-04-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 03-09-2023 12-31-2022 10-K
8 11-08-2022 09-30-2022 10-Q
9 08-08-2022 06-30-2022 10-Q
10 05-09-2022 03-31-2022 10-Q
11 03-15-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-12-2021 06-30-2021 10-Q
14 05-13-2021 03-31-2021 10-Q
15 03-18-2021 12-31-2020 10-K
16 11-10-2020 09-30-2020 10-Q
17 08-13-2020 06-30-2020 10-Q
18 05-15-2020 03-31-2020 10-Q
19 03-10-2020 12-31-2019 10-K
20 11-12-2019 09-30-2019 10-Q
21 08-14-2019 06-30-2019 10-Q
22 04-29-2019 03-31-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 precision-biosciences-secures-13m-from-imugene-convertible-note-maturity-as-part-of-azer-cel-deal

-- Payment includes $9.75 million cash and $3.25 million in Imugene Limited ordinary shares-- --The addition of this cash furt...

 hc-wainwright--co-reiterates-buy-on-precision-biosciences-maintains-60-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Precision BioSciences (NASDAQ:DTIL) with a Buy and maintains $60...

 precision-biosciences-showcases-arcus-platform-at-mitochondrial-medicine-2024

Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to ...

 precision-biosciences-to-present-preclinical-data-on-hepatitis-b-treatment-at-easl-congress

Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to ...

 hc-wainwright--co-reiterates-buy-on-precision-biosciences-maintains-60-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Precision BioSciences (NASDAQ:DTIL) with a Buy and maintains $60...

 hc-wainwright--co-reiterates-buy-on-precision-biosciences-maintains-60-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Precision BioSciences (NASDAQ:DTIL) with a Buy and maintains $60...

 precision-biosciences-q1-eps-170-beats-191-estimate-sales-1758m-beat-602m-estimate

Precision BioSciences (NASDAQ:DTIL) reported quarterly earnings of $1.70 per share which beat the analyst consensus estimate of...

 precision-biosciences-announces-receipt-of-fda-fast-track-designation-for-ecur-506-iecures-program-for-the-treatment-of-neonatal-onset-ornithine-transcarbamylase-deficiency

Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to ...

 guggenheim-initiates-coverage-on-precision-biosciences-with-buy-rating-announces-price-target-of-19

Guggenheim analyst Debjit Chattopadhyay initiates coverage on Precision BioSciences (NASDAQ:DTIL) with a Buy rating and anno...

 hc-wainwright--co-reiterates-buy-on-precision-biosciences-maintains-60-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Precision BioSciences (NASDAQ:DTIL) with a Buy and maintains $60...

 precision-biosciences-announces-return-of-programs-and-conclusion-of-collaboration-with-prevail-therapeutics

- Productive collaboration advanced three programs and demonstrated proof of concept of ARCUS for gene excision and gene insert...

 iecure-announces-fda-clearance-of-ind-application-for-ecur-506-to-initiate-otc-hope-trial-for-treatment-of-neonatal-onset-ornithine-transcarbamylase-deficiency-in-the-us-note-iecure-has-licensed-the-arcus-nuclease-for-ecur-506-from-precision-biosciences

Clinical trial sites in the United States, United Kingdom, and Australia will evaluate ECUR-506, an investigational gene editin...

 hc-wainwright--co-maintains-buy-on-precision-biosciences-adjusts-price-target-to-60

HC Wainwright & Co. analyst Patrick Trucchio maintains Precision BioSciences (NASDAQ:DTIL) with a Buy, adjusts target to...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION